Expression of claudin 10 protein in hepatocellular carcinoma: impact on survival

Journal of Cancer Research and Clinical Oncology - Tập 137 - Trang 1213-1218 - 2011
G. W. Huang1, X. Ding2, S. L. Chen3, L. Zeng3
1Department of General Surgery, Xiangya Hospital, Central South University, Changsha, People’s Republic of China
2Department of Organ Transplantation, Xiangya Hospital, Central South University, Changsha, People’s Republic of China
3Department of Pathology, Hunan Provincial Tumor Hospital, Changsha, People’s Republic of China

Tóm tắt

To investigate the expression of claudin 10 in hepatocellular carcinoma (HCC) and the impact on angiogenesis and the postoperative survival of HCC patients. The expression of claudin 10 protein was analyzed on samples from 99 HCC patients undergoing hepatectomy with immunohistochemistry and 31 fresh specimens with Western blotting. We examined the relationship between claudin 10 expression with clinicopathological factors, microvessel density (MVD), and postoperative survival. Western blotting and immunohistochemical staining showed that claudin 10 protein was highly expressed in HCC, compared with paraneoplastic liver tissue and normal liver tissue (P < 0.01). Claudin 10 protein expression levels were significantly higher in HCC specimens with microscopic venous invasion (P < 0.01). MVD in HCC increased with enhanced claudin 10 expression (P < 0.01). Kaplan–Meier survival analysis revealed that HCC patients with high claudin 10 expression had significantly shorter overall survival (P = 0.01). Multivariate analysis showed that claudin 10 expression was an independent prognostic indicator for postoperative overall survival of HCC patients (P < 0.01). Claudin 10 protein is highly expressed in HCC tissue and is closely related to angiogenesis. Claudin 10 protein could be a useful marker to predict poor prognosis of HCC patients after hepatectomy.

Tài liệu tham khảo

Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22(17):3531–3539

Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, Fan ST, So S (2005) Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 11(2 pt 1):551–556

Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, Ahn G, Shin YK (2007) Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 22(11):1185–1195

Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital death. Ann Surg 229(3):322–330

He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK (2005) Major causes of death among men and women in China. N Engl J Med 353(11):1124–1134

Huang GW, Yang LY (2002) Metallothionein expression in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 8(4):650–653

Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 11(11):1705–1708

Huang GW, Tao YM, Ding X (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54(2):389–394

Hubert C, Sempoux C, Rahier J, Horsmans Y, Geubel A, Van Beers BE, Annet L, Zech F, Leonard D, Giqot JF (2007) Prognostic risk factors of survival after resection of hepatocellular carcinoma. Hepatogastroenterology 54(78):1791–1797

Ip YC, Cheung ST, Lee YT, Ho JC, Fan ST (2007) Inhibition of hepatocellular carcinoma invasion by suppression of claudin- 10 in HLE cells. Mol Cancer Ther 6(11):2858–2867

Li J, Chigurupati S, Agarwal R, Mughal MR, Mattson MP, Becker KG, Wood WH 3rd, Zhang Y, Morin PJ (2009) Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther 8(19):1814–1822

Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43(6):979–992

Morita K, Tsukita S, Miyachi Y (2004) Tight junction-associated protein (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen’s disease. Br J Dermatol 151(2):328–334

Németh Z, Szász AM, Tátrai P, Németh J, Gyorffy H, Somorácz A, Szíjártó A, Kupcsulik P, Kiss A, Schaff Z (2009) Claudin-1, -2, -3, -4, -7, -8, and–10 protein expression in biliary tract cancers. J Histochem Cytochem 57(2):113–121

Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic caner: support for use as a therapeutic target. Am J Clin Pathol 121(2):226–230

Rangel LB, Agarwal R, D’Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9(7):2567–2575

Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18(4):511–518

Sanada Y, Yoshida K, Itoh H (2007) Comparison of CT enhancement patterns and histologic features in hepatocellular carcinoma up to 2 cm: assessment of malignant potential with claudin-10 immunohistochemistry. Oncol Rep 17(5):1177–1182

Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O’Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112(1):14–25

Sherman M (2008) Recurrence of hepatocellular carcinoma. N Engl J Med 359(19):2045–2047

Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA (2002) Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62(14):3971–3979

Tokes AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7(2):R296–R305

Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, Liu HL (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90(12):2349–2355

Wang SM, Ooi LL, Hui KM (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13(21):6275–6283

Thông tin
Thông tin xuất bản

Journal of Cancer Research and Clinical Oncology

Tập 137

1213-1218

Thông tin tác giả